Literature DB >> 23732199

[Prevention of congenital toxoplasmosis in a Buenos Aires hospital].

Liliana Carral1, Federico Kaufer, Patricia Olejnik, Cristina Freuler, Ricardo Durlach.   

Abstract

The prevention of congenital toxoplasmosis is based on providing information to women, serologic diagnosis and treatment of the infected mother and child. In this article we present the results of 12 years of implementation of a congenital toxoplasmosis prevention program in which we measured the mother's infection incidence rate, the transmission rate and the number and severity of infection in newborns. The study was performed on 12035 pregnant women in the period 2000-2011. The prevalence rate of antibodies against Toxoplasma gondii was 18.33% (2206/12035). Thirty-seven out of 9792 susceptible women presented acute infection and the mother's infection incidence rate was 3.78 per 1000 births. The transplacental transmission rate was 5.4% (2/37). Two newborns presented congenital toxoplasmosis infection, one had no clinical signs while the other presented strabismus and chorioretinitis. Thirty-five infected mothers and the two children with congenital infection were treated. The transmission rates obtained allow consider this prevention program as a valid resource to minimize the impact of congenital toxoplasmosis.

Entities:  

Keywords:  congenital toxoplasmosis; prevention; serology

Mesh:

Substances:

Year:  2013        PMID: 23732199

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  7 in total

1.  Fetomaternal and Pediatric Toxoplasmosis.

Authors:  Helieh S Oz
Journal:  J Pediatr Infect Dis       Date:  2017-12       Impact factor: 0.293

2.  Toxoplasmosis among pregnant women: high seroprevalence and risk factors in Kinshasa, Democratic Republic of Congo.

Authors:  Yobi Doudou; Piarroux Renaud; L'Ollivier Coralie; Franck Jacqueline; Situakibanza Hypolite; Muhindo Hypolite; Mitashi Patrick; Inocêncio da Luz Raquel Andreia; Marc Van Sprundel; Boelaert Marleen; Jean-Pierre Van Geertruyden; Lutumba Pascal
Journal:  Asian Pac J Trop Biomed       Date:  2014-01

3.  Seroprevalence and risk factors of Toxoplasma gondii infection in pregnant women following antenatal care at Mizan Aman General Hospital, Bench Maji Zone (BMZ), Ethiopia.

Authors:  Fira Abamecha; Hasen Awel
Journal:  BMC Infect Dis       Date:  2016-09-01       Impact factor: 3.090

4.  Seroprevalence of Toxoplasma gondii among pregnant women attending antenatal clinics at Hawassa University comprehensive specialized and Yirgalem General Hospitals, in Southern Ethiopia.

Authors:  Demissie Assegu Fenta
Journal:  BMC Infect Dis       Date:  2019-12-16       Impact factor: 3.090

5.  Isolation and molecular characterization of Toxoplasma gondii from placental tissues of pregnant women who received toxoplasmosis treatment during an outbreak in southern Brazil.

Authors:  Camila E Minuzzi; Luiza Pires Portella; Patricia Bräunig; Luis Antonio Sangioni; Aline Ludwig; Luciane Silva Ramos; Liliane Pacheco; Camila Ribeiro Silva; Flávia Caselli Pacheco; Ivone Andreatta Menegolla; Lourdes Bonfleur Farinha; Priscila Pauli Kist; Regina Mitsuka Breganó; Beatriz de Souza Lima Nino; Felippe Danyel Cardoso Martins; Thais Cabral Monica; Fernanda Pinto Ferreira; Isadora Britto; Ariana Signori; Kerlei Cristina Medici; Roberta Lemos Freire; João Luis Garcia; Italmar Teodorico Navarro; Cledison Marcio Difante; Fernanda Silveira Flores Vogel
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

6.  Toxoplasma gondii seropositivity associated to peri-urban living places in pregnant women in a rural area of Buenos Aires province, Argentina.

Authors:  Elías M Rivera; Silvina N Lavayén; Paola Sánchez; Carlos M A Martins; Etelvina Gómez; Jorge P Rodríguez; Marcela E Arias; Andrea P Silva; Sergio O Angel
Journal:  Parasite Epidemiol Control       Date:  2019-10-09

Review 7.  Maternal and congenital toxoplasmosis, currently available and novel therapies in horizon.

Authors:  Helieh S Oz
Journal:  Front Microbiol       Date:  2014-07-24       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.